(GMAB) Genmab AS - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 16.631m USD | Total Return: 31.5% in 12m
Antibodies, Cancer Therapies, Immunotherapy, Biotechnology
Total Rating 60
Safety 69
Buy Signal -0.55
Biotechnology
Industry Rotation: -6.3
Industry Rotation: -6.3
Market Cap:
16.6B
Avg Turnover: 40.7M
Avg Turnover: 40.7M
Risk 3d forecast
Volatility33.0%
VaR 5th Pctl5.82%
VaR vs Median7.01%
Reward TTM
Sharpe Ratio0.95
Rel. Str. IBD38
Rel. Str. Peer Group25.3
Character TTM
Beta0.597
Beta Downside0.712
Hurst Exponent0.507
Drawdowns 3y
Max DD57.56%
CAGR/Max DD-0.24
CAGR/Mean DD-0.41
EPS (Earnings per Share)
EPS CAGR: -25.90%
EPS Trend: 15.2%
EPS Trend: 15.2%
Last SUE: -0.23
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: -28.49%
Rev. Trend: -46.5%
Rev. Trend: -46.5%
Last SUE: -0.63
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: GMAB Genmab AS
Genmab A/S is a Denmark-based biotechnology firm specializing in antibody-based therapies for oncology and other chronic diseases. The company’s commercial portfolio includes EPKINLY/TEPKINLY for lymphoma and Tivdak for cervical cancer, alongside a diverse pipeline of candidates targeting solid tumors and hematological malignancies.
The company operates through a high-leverage partnership model, collaborating with global pharmaceutical leaders such as AbbVie, Johnson & Johnson, and Pfizer to co-develop and commercialize its proprietary antibody platforms. In the biotechnology sector, this strategy mitigates the high capital expenditure associated with late-stage clinical trials while securing royalty streams from established blockbusters like DARZALEX and Kesimpta.
Evaluating the long-term sustainability of these royalty structures on ValueRay can provide deeper insight into the companys valuation. Genmab continues to expand its pipeline into niche indications, including rare diseases such as thyroid eye disease and hemophilia A, utilizing advanced antibody formats to address unmet medical needs.
- Darzalex royalty revenue streams drive core earnings and cash flow stability
- Epkinly market penetration in lymphoma indications dictates near-term growth trajectory
- Clinical trial data for Acasunlimab and Rinatabart Sesutecan impacts pipeline valuation
- Expansion of Johnson & Johnson partnership products influences long-term royalty projections
- Regulatory approval timelines for cervical and lung cancer treatments affect revenue diversification
Piotroski VR‑10 (Strict)
6.5
| Net Income: 2.61b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -1.08 > 1.0 |
| NWC/Revenue: 15.78% < 20% (prev 154.3%; Δ -138.5% < -1%) |
| CFO/TA 0.10 > 3% & CFO 1.23b > Net Income 2.61b |
| Net Debt (3.83b) to EBITDA (3.81b): 1.01 < 3 |
| Current Ratio: 2.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (638.6m) vs 12m ago -0.12% < -2% |
| Gross Margin: 93.60% > 18% (prev 0.95%; Δ 9.27k% > 0.5%) |
| Asset Turnover: 33.14% > 50% (prev 32.90%; Δ 0.24% > 0%) |
| Interest Coverage Ratio: 14.90 > 6 (EBITDA TTM 3.81b / Interest Expense TTM 216.3m) |
Altman Z''
3.22
| A: 0.11 (Total Current Assets 2.57b - Total Current Liabilities 1.18b) / Total Assets 12.38b |
| B: 0.33 (Retained Earnings 4.09b / Total Assets 12.38b) |
| C: 0.12 (EBIT TTM 3.22b / Avg Total Assets 26.67b) |
| D: 0.56 (Book Value of Equity 3.76b / Total Liabilities 6.69b) |
| Altman-Z'' Score: 3.22 = A |
Beneish M
-3.06
| DSRI: 0.25 (Receivables 1.03b/6.32b, Revenue 8.84b/13.47b) |
| GMI: 1.01 (GM 93.60% / 94.95%) |
| AQI: 2.19 (AQ_t 0.77 / AQ_t-1 0.35) |
| SGI: 0.66 (Revenue 8.84b / 13.47b) |
| TATA: 0.11 (NI 2.61b - CFO 1.23b) / TA 12.38b) |
| Beneish M-Score: -3.06 (Cap -4..+1) = AA |
What is the price of GMAB shares?
As of May 18, 2026, the stock is trading at USD 26.54 with a total of 1,362,310 shares traded.
Over the past week, the price has changed by +0.42%, over one month by -7.04%, over three months by -11.53% and over the past year by +31.52%.
Over the past week, the price has changed by +0.42%, over one month by -7.04%, over three months by -11.53% and over the past year by +31.52%.
Is GMAB a buy, sell or hold?
Genmab AS has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy GMAB.
- StrongBuy: 4
- Buy: 1
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the GMAB price?
| Analysts Target Price | 37.6 | 41.8% |
Genmab AS (GMAB) - Fundamental Data Overview
as of 14 May 2026
P/E Trailing = 20.6794 P/E Forward = 15.674
P/S = 4.2632
P/B = 2.8556
P/EG = 1.6808
Revenue TTM = 8.84b USD
EBIT TTM = 3.22b USD
EBITDA TTM = 3.81b USD
Long Term Debt = 5.00b USD (from longTermDebt, last fiscal year)
Short Term Debt = 293.0m USD (from shortTermDebt, last quarter)
Debt = 5.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.83b USD (from netDebt column, last quarter)
Enterprise Value = 20.46b USD (16.63b + Debt 5.35b - CCE 1.52b)
Interest Coverage Ratio = 14.90 (Ebit TTM 3.22b / Interest Expense TTM 216.3m)
EV/FCF = 17.81x (Enterprise Value 20.46b / FCF TTM 1.15b)
FCF Yield = 5.61% (FCF TTM 1.15b / Enterprise Value 20.46b)
FCF Margin = 13.00% (FCF TTM 1.15b / Revenue TTM 8.84b)
Net Margin = 29.58% (Net Income TTM 2.61b / Revenue TTM 8.84b)
Gross Margin = 93.60% ((Revenue TTM 8.84b - Cost of Revenue TTM 565.2m) / Revenue TTM)
Gross Margin QoQ = 92.75% (prev 92.34%)
Tobins Q-Ratio = 1.65 (Enterprise Value 20.46b / Total Assets 12.38b)
Interest Expense / Debt = 2.10% (Interest Expense 112.4m / Debt 5.35b)
Taxrate = 28.38% (21.1m / 74.3m)
NOPAT = 2.31b (EBIT 3.22b * (1 - 28.38%))
Current Ratio = 2.18 (Total Current Assets 2.57b / Total Current Liabilities 1.18b)
Debt / Equity = 0.94 (Debt 5.35b / totalStockholderEquity, last quarter 5.68b)
Debt / EBITDA = 1.01 (Net Debt 3.83b / EBITDA 3.81b)
Debt / FCF = 3.33 (Net Debt 3.83b / FCF TTM 1.15b)
Total Stockholder Equity = 12.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.80% (Net Income 2.61b / Total Assets 12.38b)
RoE = 20.56% (Net Income TTM 2.61b / Total Stockholder Equity 12.72b)
RoCE = 18.19% (EBIT 3.22b / Capital Employed (Equity 12.72b + L.T.Debt 5.00b))
RoIC = 31.23% (NOPAT 2.31b / Invested Capital 7.39b)
WACC = 6.48% (E(16.63b)/V(21.98b) * Re(8.08%) + D(5.35b)/V(21.98b) * Rd(2.10%) * (1-Tc(0.28)))
Discount Rate = 8.08% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -49.44 | Cagr: -1.32%
[DCF] Terminal Value 83.16% ; FCFF base≈2.39b ; Y1≈2.16b ; Y5≈1.87b
[DCF] Fair Price = 72.84 (EV 48.55b - Net Debt 3.83b = Equity 44.72b / Shares 613.9m; r=6.48% [WACC]; 5y FCF grow -12.02% → 3.0% )
EPS Correlation: 15.22 | EPS CAGR: -25.90% | SUE: -0.23 | # QB: 0
Revenue Correlation: -46.54 | Revenue CAGR: -28.49% | SUE: -0.63 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.30 | Chg30d=+0.03% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.32 | Chg30d=-6.02% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=1.09 | Chg30d=-7.07% | Revisions=+0% | GrowthEPS=-28.9% | GrowthRev=+16.9%
EPS next Year (2027-12-31): EPS=1.87 | Chg30d=-0.99% | Revisions=-20% | GrowthEPS=+70.8% | GrowthRev=+18.5%
[Analyst] Revisions Ratio: -20%